Semaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.
By Tarun Sai LomteReviewed by Lily Ramsey, LLMAug 27 2024 In a recent study published in The Lancet, researchers investigated whether semaglutide is beneficial in persons with atherosclerotic cardiovascular disease and a history of heart failure .
The rise in obesity is also associated with an increased prevalence of heart failure. Most patients with obesity and heart failure have heart failure with preserved ejection fraction, which is likely causally related to the pathological outcomes of obesity. Subjects were randomized to receive a placebo or increasing doses of once-weekly semaglutide for 16 weeks.
Findings Overall, 17,604 patients were randomized to semaglutide or placebo groups between October 31, 2018, and March 31, 2021. Their mean age and BMI were 61.6 years and 33.4 kg/m2, respectively. The incidence of heart failure with preserved ejection fraction was associated with higher baseline BMI. Patients with heart failure with reduced ejection fraction had lower mean systolic blood pressure than those with heart failure with preserved ejection fraction.
Placebo subjects with heart failure at baseline had elevated rates of all outcomes relative to those without heart failure. Semaglutide improved all outcome measures in patients with heart failure.
Heart Failure Semaglutide Agonist Cardiovascular Disease Diabetes Glucagon Glucagon-Like Peptide-1 Mortality Myocardial Infarction Obesity Placebo Receptor Stroke Weight Loss
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Semaglutide may reduce smoking risks for diabetes patientsSemaglutide shows promise in reducing tobacco use disorder-related health encounters in patients with type 2 diabetes, but further clinical trials are needed to confirm its efficacy.
Read more »
Semaglutide seems beneficial for comorbid type 2 diabetes mellitus, tobacco use disorderFor patients with type 2 diabetes mellitus (T2DM) and tobacco use disorder (TUD), new use of semaglutide is associated with lower risk of TUD-related health care measures compared with other antidiabetes medications, according to a study published online July 30 in the Annals of Internal Medicine.
Read more »
Illegal 'semaglutide' slimming drugs sold in salons and onlineBBC Investigations speaks to people damaged by illegal and often fake slimming drug injection kits.
Read more »
Semaglutide products being sold online without prescriptionsSemaglutide products are being sold online, with products likely unregistered or unlicensed, according to a research letter published online Aug. 2 in JAMA Network Open.
Read more »
Semaglutide-linked suicidal ideation identified in disproportionality analysisSemaglutide-associated suicidal ideation has been identified in a disproportionality analysis, according to a study published online Aug. 20 in JAMA Network Open.
Read more »
Clarification urgently needed for detected signal of semaglutide-linked suicidal ideationResearchers investigate the potential link between the obesity drugs semaglutide and liraglutide and suicidal or self-injurious adverse drug reactions.
Read more »